Latest Report Alleges Apotex Founder and Wife Victims of Contract Killing

                                                                                          Issue # 2603 | January 22nd, 2018      
















































































































































































News Alert



Latest Report Alleges Apotex Founder and Wife Victims of Contract Killing

It's double murder, not murder-suicide. Barry and Honey Sherman were killed in what looks like a professional, contract killing. That's the conclusion of a variety of experts who have been hired by the family to probe the case. This comes after a second autopsy by a leading forensic pathologist discovered markings on the Shermans' wrists, an indication that at some point their hands were tied together, though no rope or other ties were found near the bodies. For their part, the Toronto police are not providing any new information or comment on the findings of the families experts and maintain their classification of the deaths as "suspicious".  Learn More




Teva Reorganization Claims 200+ Jobs in Pennsylvania

In WARN notices filed with the state of Pennsylvania, Teva has made public that it is laying off 200+ workers this month. Those affected include 65 persons at the company's sites in Horsham and North Wales, 96 persons at sites in Frazer and Great Valley, and 47 at the site in West Chester. These job cuts come amid a global restructuring on the part of Teva that will ultimately eliminate 25% of its global workforce. Roughly 3,000 of whom are slated to effect employees in  Israel . This has resulted in striking workers and calls by the Israel government to increase the number of cuts to jobs abroad to protect jobs at home.  Learn More




Biogen, UCB and Others Rumored 
to Have Acorda on Their Radar

Following a successful appearance at this year's J.P. Morgan conference, at which the company showcased  recent sales successes and favorable projections for its two Parkinson's drugs,  Acorda is rumored to be on the acquisition radar of Biogen, UCB and others. Alert readers will recall that Acorda had a rough road in the latter part of 2017.  Patient deaths led to the ending of enrollment in the Phase III clinical trial of a lead drug candidate and subsequent abandonment of further associated research. All of this while the company dealt with the loss of 4 of the 5 patents on its drug Ampyra, the one remaining patent for which expires later this year, and a 20% cut to its workforce.  Learn More

Quote Alert

On this Day Alert


TED Alert

Why are these 32 Symbols Found 
in Caves All Over Europe


Written language, the hallmark of human civilization, didn't just suddenly appear one day. Thousands of years before the first fully developed writing systems, our ancestors scrawled geometric signs across the walls of the caves they sheltered in. Paleoanthropologist, rock art researcher and TED Senior Fellow Genevieve von Petzinger has studied and codified these ancient markings in caves across Europe. The uniformity of her findings suggest that graphic communication, and the ability to preserve and transmit messages beyond a single moment in time, may be much older than we think.  Learn More

Poll Alert

Do you play video games? If yes, which of these is your preferred type of game?
 
 
  
 
   
 
 
 
 
 




Bioprocess Alert

Aseptic Gowning for the Cleanroom


One of the primary safeguards that life science companies use to help prevent contamination in cleanroom operations is Gowning. Gowning is basically putting on clothing, in this case layers of specially designed garments, covers, masks and gloves that isolates your body from the clean room environment.  Learn More

Market Alert

Event Alert: Webinar




Regulatory Alert



Novartis Aims for U.S. Approval 
of Humira Biosimilar

In an announcement this week, Novartis made public that it is seeking U.S. regulatory approval for what would be the third biosimilar of AbbVie's blockbuster drug Humira. To that end, Novartis, more specifically its generic unit Sandoz, has had its application for a biosimilar of Humira accepted by the U.S. FDA. Humira, which last year earned more than $16 billion for AbbVie, is a prime target for biosimilar competition. However, to date AbbVie has successfully surrounded the inflammatory disease drug with a thicket of patents designed to defend its lucrative market. Learn More

Discovery Alert



Secrets of Longevity Protein 
Revealed in New Study

Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure of one of these proteins, beta-Klotho, illuminating its intricate mechanism and therapeutic potential. The study findings, published in Nature, could have implications for therapies developed to treat a wide range of medical conditions, including diabetes, obesity, and certain cancers, the researchers said. The Klotho family of two receptor proteins are located on the surface of cells of specific tissues. The proteins bind to a family of hormones, designated endocrine FGFs, that regulate critical metabolic processes in the liver, kidneys, and brain, among other organs.  Learn More


Project Alert



AbbVie to Expand Manufacturing 
Facility in Ireland

AbbVie has made public plans to expand its manufacturing facility in Sligo, Ireland to support the growth of its Oncology pipeline. The $138 million investment in new sterile manufacturing technology at the Ballytivnan site will help deliver promising treatments for cancers with significant unmet medical needs. The expansion will create approximately 100 new jobs over the course of 3 years in a variety of technical and manufacturing positions. The project is supported by the Irish Government. AbbVie's commercial headquarters is based in Dublin, Ireland as is a separate international manufacturing and engineering services center. AbbVie has two manufacturing plants in Sligo and one in Cork. Learn More

Patent Alert



pH Sensor for Single Use Equipment

A U.S. Patent for a "pH Sensor for Single Use Equipment"  was awarded to Emerson on January 16th, 2018The present invention is a single use pH sensor housing for a single use container is provided. The single use pH sensor housing includes a compartment configured to house a single use pH sensor. In one embodiment, the single use pH sensor housing comprises an actuator configured, when actuated, to transition the single use pH sensor from a storage position to a deployed position. In the storage position, the pH sensor is in fluidic contact with a buffer solution. In the deployed position, the single use pH sensor is in fluidic contact with an interior of the single use container. During the transition from the storage position to the deployed position, the buffer solution moves from a sensor portion of the compartment to a storage portion of the compartment such that the buffer solution is isolated from contact with the interior of the single use container.  Learn More


Focus Alert


Multi-Chamber Single-Use Bioreactor, 
A Proof of Concept Prototype

Stirred tank single-use bioreactors have proven their capability to successfully replace their stainless-steel counterparts in the biopharmaceutical industry. To date, however, only a five-fold volume expansion is achievable in a single-use stirred tank bioreactor, which in turn, necessitates intermediate equipment to scale up the culture to production volume. This study introduces a two-chamber single-use bioreactor that is capable of cell culture expansion from 1 to 50 L. The prototype is a proof of concept that can help users save costs of purchase and qualification of equipment, reduce factory footprint, and reduce the risk of contamination during culture transfer from one intermediate bag to another. The prototype is made of two chambers of different volumes, interconnected as a single, closed system. The design and construction of the prototype is described in detail and results from the engineering characterization (e.g., mixing time, power input per unit volume, and oxygen mass transfer coefficient) are reported for both chambers. The results are in good agreement with general criteria proposed in literature for bioreactor design and with published data for commercially available bioreactors. Further, the concept is not limited to the two-chamber design presented in this study; additional chambers can be integrated along with different volumes, geometries, mixing, sparging, and heating approaches.  Learn More


Job Alert


Oncobiologics is seeking to fill a Director Cell Culture Process Development position at their site in Cranbury, New Jersey. This position will lead a team of 4-6 scientists/engineers and serve as subject matter expert related to upstream process development. This includes all process and manufacturing related activities, including risk assessments, characterization, investigations, regulatory interactions, and project team requirements. Learn More



Utah State University is seeking to fill a Synthetic Biomanufacturing Program Manager position at their site in Logan, Utah. The successful candidate for this position will manage the Utah Science Technology and Research Synthetic Biomanufacturing Facility. Overseeing and assisting with the production of bioproducts in fermenters of varying sizes.  Learn More




Distek is seeking to fill a Biotechnology Product Line Manager position at their site in Central, New Jersey. 
The major responsibilities associated with this position include the performance of product demonstrations, application studies and technical presentations.  Learn More



AGC Biologics is seeking to fill a Director, BD Enterprise Operations position  at their site in Seattle, Washington. This position has primary responsibility for leading our Business Development Operations with a focus on enabling our global sales of contract manufacturing services.  Learn More

Fact Alert